Description

Tirzepatide 25 mg — Dual Agonist Pen for Metabolic Research

Peptilife Tirzepatide 25 mg delivers the powerful dual GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) receptor agonist mechanism in a convenient, ready-to-use pen format. Tirzepatide acts simultaneously on two key metabolic receptors, making it one of the most advanced peptides studied for appetite regulation, body weight reduction and glucose metabolism optimization.

Each pen contains 25 mg of high-purity Tirzepatide, formulated for precise subcutaneous administration. Purity: ≥98% by HPLC. Ideal for advanced metabolic research applications.

Key Benefits

• Dual agonist: GLP-1R + GIPR — synergistic action on two metabolic pathways
• 25 mg pre-filled pen | Purity: ≥98% — verified by HPLC analysis
• Promotes significant reduction in appetite and caloric intake
• Supports accelerated fat loss and preservation of lean body mass
• Improves insulin sensitivity and glucose metabolism markers
• Storage: 2–8°C (refrigerated) — do not freeze
• Ready-to-use pen format — no reconstitution required

Technical Specifications

• Active ingredient: Tirzepatide
• Concentration: 25 mg/pen
• Format: Pre-filled subcutaneous injection pen
• Purity: ≥98% (HPLC verified)
• Mechanism: Dual GLP-1/GIP receptor agonist
• Storage: 2–8°C | Protect from light

For research purposes only. Not for human consumption. This product is intended exclusively for in vitro research and scientific study.